Lung Cancers Today

Advertisement
Yuanbin Chen, MD, PhDASCO 2024: Focus on Lung Cancer | July 18, 2024
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
View More
Ivania Valdés ArayaNon-Small Cell Lung Cancer | July 18, 2024
A researcher discusses the implications of identifying potentially pathogenic bacteria in adenocarcinoma tumors.
Katie KoskoNon-Small Cell Lung Cancer | July 17, 2024
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
Valsamo Anagnostou, MD, PhDNon-Small Cell Lung Cancer | July 17, 2024
Valsamo Anagnostou, MD, PhD, discusses advances in the field and her lab's research on the topic.
Katie KoskoLung Cancer | July 15, 2024
A new study showed surprising results about lung cancer screening during the pandemic.
Cecilia BrownNon-Small Cell Lung Cancer | July 12, 2024
The drug combination showed "reduced efficacy" in terms of PFS and OS, officials said.
Cecilia BrownNon-Small Cell Lung Cancer | July 11, 2024
IDE397, a “potential first-in-class” MAT2A inhibitor, is under evaluation in phase 2 clinical trials.
Leah LawrenceNon-Small Cell Lung Cancer | July 12, 2024
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Cecilia BrownNon-Small Cell Lung Cancer | July 9, 2024
The European Commission’s approval is based on results from the phase 3 FLAURA2 trial.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 8, 2024
Most patients who received adjuvant osimertinib achieved MRD negativity.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 5, 2024
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 4, 2024
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 3, 2024
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 2, 2024
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
David R. Spigel, MDASCO 2024: Focus on Lung Cancer | July 1, 2024
Dr. Spigel speaks about how the American Society of Clinical Oncology Annual Meeting inspires collaboration and discovery.
Katie KoskoLung Cancer | June 28, 2024
Researchers evaluated primary ambulatory thromboprophylaxis because thrombosis is a leading cause of death in these patients.
Cecilia BrownNon-Small Cell Lung Cancer | June 27, 2024
The approval is based upon results from the phase 3 FLAURA2 trial and a subgroup analysis of a cohort from China.
Narjust Florez, MD, FASCOASCO 2024: Focus on Lung Cancer | June 27, 2024
Narjust Florez, MD, FASCO, discusses her research on the unique needs of young patients with lung cancer.
Laila Gharzai, MDASCO 2024: Focus on Lung Cancer | June 27, 2024
Laila Gharzai, MD, discusses her research on the financial impacts of lung biomarker testing.
Eric Singhi, MDASCO 2024: Focus on Lung Cancer | June 26, 2024
Dr. Singhi discusses practice-changing data and historic advancements in lung cancer.
Advertisement
Advertisement
Advertisement
Latest News

July 18, 2024